



H E S I

**ILSI Health and Environmental Sciences Institute**

# **2009 HESI Annual Meeting**

## **Emerging Issues Meeting**

**January 20, 2009**

**Tucson, AZ**

**Dr. Ruth Lightfoot-Dunn**

**(Amgen Inc.)**

**Chair, HESI Emerging Issues Steering Committee**



H E S I

# 2009 EMERGING ISSUES STEERING COMMITTEE



# 2009 Emerging Issues Steering Committee

*Elected by HESI Assembly of Members, January 19, 2009*

H E S I

## Leadership:

**Chair:** **Dr. B. Bhaskar Gollapudi**  
(The Dow Chemical Company)  
(term expires January 2012)

**Vice Chair:** **Dr. Ernie Harpur**  
(sanofi-aventis)  
(term expires January 2014)

**Past Chair:** **Dr. Ruth Lightfoot-Dunn**  
(Amgen, Inc.)  
(term expires January 2010)



H E S I

# 2009 Emerging Issues Steering Committee

*New members elected by HESI Assembly of Members,  
January 19, 2009*

## **MEMBERS-AT-LARGE**

**Dr. Karen L. Blackburn – newly elected**

(The Procter and Gamble Company) (term expires January 2012)

**Dr. Werner H. Bomann – newly elected**

(Bayer CropScience) (term expires January 2012)

**Dr. Stuart Cagen**

(Shell Health Services) (term expires January 2010)

**Dr. A. Robert Schnatter**

(ExxonMobil Biomedical Sciences, Inc.) (term expires January 2011)

**Dr. James L. Stevens – newly elected**

(Eli Lilly and Company) (term expires January 2010)

***(One Member-at-Large to be determined.)***



H E S I

# 2009 Emerging Issues Steering Committee

*New scientific advisors elected by HESI Assembly of Members,  
January 19, 2009*

## SCIENTIFIC ADVISORS

### **Dr. Toshihisa Ishikawa** – newly elected

(Tokyo Institute of Technology) (term expires January 2012)

### **Dr. Ian Kimber**

(University of Manchester) (term expires January 2010)

### **Dr. Serrine S. Lau**

(University of Arizona) (term expires January 2011)

### **Dr. Klaus Olejniczak**

(Federal Institute for Drugs and Medical Devices, Germany) (term expires January 2010)

### **Dr. Kenneth Ramos**

(University of Louisville) (term expires January 2010)

### **Dr. Leonard V. Sacks**

(US Food and Drug Administration) (term expires January 2011)

### **Dr. Sally S. Tinkle**

(National Institute of Environmental Health Sciences) (term expires January 2011)

### **Dr. Gary Williams** – re-elected

(New York Medical College) (term expires January 2012)

### **Dr. Hal Zenick** – re-elected

(US Environmental Protection Agency) (term expires January 2012)



H E S I

# **Emerging Issues Steering Committee**

## ***Outgoing EISC Participants***

**Dr. Karen Augustine**

**Member-at-Large**

(Bristol-Myers Squibb Research Institute)

**Dr. Gary Carlson**

**Scientific Advisor**

(Purdue University)

**Dr. Louis Mylecraine**

**Member-at-Large**

(Bayer Healthcare Pharmaceuticals)



H E S I

# EMERGING ISSUES PROCESS



H E S I

## **EMERGING ISSUES PROCESS: ISSUE IDENTIFICATION**

### **Annual Survey:**

- **Distributed to HESI membership and a broad cross-section of the international scientific community.**
- **In addition to proposing new topics, respondents are asked to consider topics in the context of linkages with issues found on the HESI Scientific Map.**
- **Results from the survey are examined by the Emerging Issues Steering Committee (EISC) in the fall of each year.**
- **Using established criteria, the EISC determines which proposals are presented at the Annual Meeting.**





H E S I

## CRITERIA FOR ISSUE IDENTIFICATION AND PRIORITIZATION

- 1. The issue should be critical for the general scientific community, as well as for current and potential member companies, and should have current public health significance.**
- 2. The issue should have reasonable potential for resolution.**
- 3. The issue should be an area for which HESI has or can identify expertise to contribute.**
- 4. HESI's efforts to address the issue should not be duplicative of other groups.**



H E S I

## **EMERGING ISSUES PROCESS: SUBCOMMITTEE FORMATION**

### **Subcommittees:**

- **HESI members and constituency are asked to submit prioritizations of the topics presented at the Annual Meeting. (See yellow form in Emerging Issues meeting packet.)**
- **The EISC examines the results of the prioritization exercise and identifies one or two priority topics for HESI subcommittee formation.**
- **The Subcommittee program is developed over the next 18-24 months.**



H E S I

# NEW TOPIC PRESENTATIONS



H E S I

# Proposals for 2009 Consideration

## 15 high-quality proposals received:

- Submissions from Japan, Europe, and the US
- Two submissions from government
- One submission from an academic institution
- Industry proposals from pharmaceutical, chemical, pesticide, and consumer products sectors



H E S I

**ONE TOPIC  
WILL BE SELECTED  
FOR HESI ACTION  
IN 2009.**



H E S I

# NEW TOPIC PRESENTATIONS

## Identification of Pharmaceuticals for Validation of ToxCast

Dr. Robert Kavlock (US EPA)

Dr. Robert Chapin (Pfizer Inc.)

## Human iPS Cell Technology and Its Application to Toxicology Testing

Prof. Dr. Kenji Yasuda (Tokyo Medical and Dental University)

Dr. Samuel Cohen (University of Nebraska Medical Center)

## Improving Exposure Science and Dose Metrics for Toxicity Testing, Screening, Prioritizing, and Risk Assessment

Dr. Elaine Cohen-Hubal (US EPA)

Dr. Timothy Pastoor (Syngenta)